Literature DB >> 11228181

Serum ferritin is a marker of morbidity and mortality in hemodialysis patients.

K Kalantar-Zadeh1, B R Don, R A Rodriguez, M H Humphreys.   

Abstract

We tested the hypothesis that a high concentration of serum ferritin, a frequently used marker of iron stores in dialysis patients and an acute-phase reactant, may be a marker of morbidity and mortality in these patients. To evaluate the impact of ferritin on morbidity and mortality, we reviewed the 6-month hospitalization rates in our dialysis patients retrospectively and subsequently reviewed the mortality among these patients over a 12-month period of time prospectively. One hundred one adult hemodialysis patients (59 men and 42 women; age, 54 +/- 15 years) who had been on hemodialysis for 38 +/- 27 months were studied. All but 5 patients were on intravenous iron with similar iron administration pattern. In the retrospective cohort, ferritin's correlation coefficients for hospitalization days and frequency (both r = +0.39, P: < 0.001) were higher compared with the albumin correlations for hospitalization days (r = -0.31, P: = 0.001) and frequency (r = -0.28, P: = 0.005) and correlation coefficients remained similarly significant after case-mix adjustment. In the prospective study, the "predeath" value of serum ferritin for 17 deceased patients (891 +/- 476 ng/mL) was higher than both their "initial" value (619 +/- 345 ng/mL, P: = 0.007) and the mean ferritin value of 84 surviving and withdrawing patients (639 +/- 358 ng/mL, P: = 0.001). Although Cox proportional hazard analysis showed a significant odds ratio of death only for serum albumin and not for ferritin, logistic regression analysis using the predeath values confirmed the significant impact of both decreased serum albumin and increased serum ferritin as markers of dialysis mortality. After case-mix adjustment, the relative risks of death for a 500 ng/dL increase in serum ferritin was 2.71 (95% confidence interval, 1.06 to 7.02) and for a 0.5 g/dL decrease in serum albumin was 4.48 (95% confidence interval, 1.77 to 11.33). Hence, serum ferritin is a strong predictor of hospitalization in dialysis patients. Although serum albumin is found to be a strong long-term marker of mortality in hemodialysis patients, an increase in serum ferritin appears to be a more reliable short-term marker of death over a 12-month period. Therefore, in the setting of uniform iron administration, a high serum ferritin may be a morbidity risk factor and a recent increase in serum ferritin may carry an increase in the risk of death in these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11228181

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  40 in total

1.  Serum ferritin predicts prognosis in hemodialysis patients: the Nishinomiya study.

Authors:  Yukiko Hasuike; Hiroshi Nonoguchi; Masanori Tokuyama; Mai Ohue; Takanori Nagai; Mana Yahiro; Masayoshi Nanami; Yoshinaga Otaki; Takeshi Nakanishi
Journal:  Clin Exp Nephrol       Date:  2010-05-14       Impact factor: 2.801

2.  Low protein nitrogen appearance as a surrogate of low dietary protein intake is associated with higher all-cause mortality in maintenance hemodialysis patients.

Authors:  Vanessa A Ravel; Miklos Z Molnar; Elani Streja; Jun Chul Kim; Alla Victoroff; Jennie Jing; Debbie Benner; Keith C Norris; Csaba P Kovesdy; Joel D Kopple; Kamyar Kalantar-Zadeh
Journal:  J Nutr       Date:  2013-05-22       Impact factor: 4.798

Review 3.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

4.  Serum Ferritin Variations and Mortality in Incident Hemodialysis Patients.

Authors:  Taehee Kim; Elani Streja; Melissa Soohoo; Connie M Rhee; Rieko Eriguchi; Tae Woo Kim; Tae Ik Chang; Yoshitsugu Obi; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  Am J Nephrol       Date:  2017-07-14       Impact factor: 3.754

5.  Targeting the hepcidin-ferroportin pathway in anaemia of chronic kidney disease.

Authors:  Matthew Sheetz; Philip Barrington; Sophie Callies; Paul H Berg; Juliet McColm; Thomas Marbury; Brian Decker; Gregory L Dyas; Stephanie M E Truhlar; Robert Benschop; Donmienne Leung; Jolene Berg; Derrick R Witcher
Journal:  Br J Clin Pharmacol       Date:  2019-03-04       Impact factor: 4.335

6.  Factors affecting the body mass index, haemoglobin and serum ferritin level in students.

Authors:  Niaz Hussain Jamali; Abdul Hakeem Jamali; Aftab Ahmed Khand; Hidayatullah Mahesar; Muhammad Iqbal Arain
Journal:  Am J Blood Res       Date:  2017-06-15

7.  Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.

Authors:  Angelo Karaboyas; Jarcy Zee; Hal Morgenstern; Jacqueline G Nolen; Raymond Hakim; Kamyar Kalantar-Zadeh; Philip Zager; Ronald L Pisoni; Friedrich K Port; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-18       Impact factor: 8.237

8.  A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.

Authors:  Johann C B Nicholas
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  Reduction of a marker of oxidative stress with enhancement of iron utilization by erythropoiesis activation following epoetin beta pegol administration in iron-loaded db/db mice.

Authors:  Mariko Noguchi-Sasaki; Yusuke Sasaki; Yukari Matsuo-Tezuka; Hideyuki Yasuno; Mitsue Kurasawa; Keigo Yorozu; Yasushi Shimonaka
Journal:  Int J Hematol       Date:  2016-01-06       Impact factor: 2.490

10.  Intermittent versus maintenance iron therapy in children on hemodialysis: a randomized study.

Authors:  Ma de la Cruz Ruiz-Jaramillo; Juan Manuel Guízar-Mendoza; María de Jesús Gutiérrez-Navarro; Luis Antonio Dubey-Ortega; Norma Amador-Licona
Journal:  Pediatr Nephrol       Date:  2003-11-22       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.